Results 131 to 140 of about 3,791 (213)

¹⁷⁷Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods. [PDF]

Eur J Hosp Pharm
Donzé C, Rubira L, Santoro L, Viarasakd M, Kotzki PO, Deshayes E, Fersing C.   +6 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy Using ⁹⁰Y- and ¹⁷⁷Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by ⁶⁸Ga-DOTATATE Positron Emissions Tomography/Computer Tomography. [PDF]

Diagnostics (Basel)
Rubinstein G, Ilhan H, Bartenstein P, Lehner S, Hacker M, Todica A, Zacherl MJ, Fischer M.   +7 more
europepmc   +1 more source

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

European Journal of Nuclear Medicine and Molecular Imaging, 2022
Radionuclide therapy with 177Lu-DOTATATE is well established for patients with advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule of 7.4 GBq at four occasions.
Anna Sundlov, Katarina Sjögreen Gleisner, Jan Tennvall   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Gallbladder Uptake Mimicking Liver Metastasis on 177Lu-DOTATATE Posttherapy Scan Gallbladder Uptake on 177Lu-DOTATATE Scan

Clinical Nuclear Medicine, 2021
Abstract We represent the case of a 61-year-old man with atypical carcinoid tumor of the lung. On posttherapy 177Lu-DOTATATE whole-body scan, focal intense uptake in the inferomedial side of the liver was detected. Pretherapy 68Ga-DOTATATE PET/CT showed no sign of liver metastasis, and posttherapy diagnostic dynamic liver MRI is used to ...
Mine, Araz, Muhammet Halil, Baltacioglu, Sezer, Saglam, Mehmet Ali, Ozguven, Nuriye Ozlem, Kucuk   +4 more
openaire   +2 more sources

Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2021
Implementation of dosimetry calculations in the daily practice of Nuclear Medicine Departments is, at this time, a controversial issue, partly due to the lack of a standardized methodology that is accepted by all interested parties (patients, nuclear medicine physicians and medical physicists).
T, Monserrat Fuertes, F M, González García, M Á, Peinado Montes, M L, Domínguez Grande, N, Martín Fernández, A, Gómez de Iturriaga Piña, P, Mínguez Gabiña   +6 more
openaire   +2 more sources

Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE

Health Physics, 2022
Abstract 177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public ...
Kimyli, Recca, Aeman, Muneeb, Christopher, Helstern, Bryan, Lemieux, Satya, Das, Aaron, Jessop   +5 more
openaire   +2 more sources

Incidental Muscle Uptake of 177Lu-DOTATATE in Peripheral Vascular Disease

Nuclear Medicine and Molecular Imaging, 2021
Somatostatin receptor (SSTR)-based imaging and therapy has emerged as well-established modality in neuroendocrine tumors. However, its role in inflammation imaging is still evolving. We present a 48-year-old male with metastatic neuroendocrine tumor who underwent lutetium-177-based somatostatin receptor-based therapy.
Piyush Aggarwal, Kunal Ramesh Chandekar, Ashwani Sood, Shakti Zerial, Rajender Kumar, Anindita Sinha   +5 more
openaire   +2 more sources

Increased 177Lu-DOTATATE Uptake in Paget Disease

Clinical Nuclear Medicine, 2013
A 45-year-old female patient was referred for peptide receptor radionuclide therapy of liver metastases of neuroendocrine origin; the patient had undergone 2 years earlier surgical resection of a grade 2 neuroendocrine neoplasm of ampulla of Vater infiltrating the duodenal submucosa and muscular layers and the neighboring pancreatic tissue.
MINUTOLI, Fabio, SINDONI, ALESSANDRO, CARDILE, DAVIDE, Giorgio, Restifo Pecorella, BALDARI, Sergio   +4 more
openaire   +3 more sources

Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors

Pancreas, 2021
Abstract Peptide receptor radionuclide therapy (PRRT) is a treatment option for somatostatin receptor–positive, unresectable or metastatic neuroendocrine tumors (NETs). Despite high disease control rates seen with PRRT, a subset of the NET population seems to have a short progression-free interval.
Hussein A, Assi, Kathleen, Hornbacker, Shagufta, Shaheen, Theresa, Wittenberg, Robyn, Silberman, Pamela L, Kunz   +5 more
openaire   +2 more sources

Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy

Clinical Nuclear Medicine, 2016
A 72-year-old man was diagnosed with well-differentiated neuroendocrine tumor of unknown primary with liver metastasis. All liver lesions were detectable only on Ga-DOTATATE PET/CT and were negative on F-FDG PET/CT. Intrahepatic Y radioembolization therapy was planned, but the hepatopulmonary shunt fraction was found to be 31.6%.
Emine, Acar, Gamze, Çapa Kaya, Hatice, Durak   +2 more
openaire   +2 more sources